WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results on 18 March 2025. The Chinese contract research, development, and ...

The Biotechnology Innovation Organization (BIO) has said it is parting company with Wuxi AppTec, while voicing support for US legislation that would block Chinese biotechs from federal funding and ...

TOLEDO, Ohio, March 3, 2025 /PRNewswire/ -- NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec's US ...

China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and ...

WuXi AppTec expects sales to grow 10% to 15% in 2025 as the fate of the BIOSECURE Act remains uncertain. And more. 1. AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer ...